Pharmaceutical Market: Bangladesh 2015

While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies, such as Bangladesh, may be a favourable strategy for any multinational pharmaceutical company – it is vital that a company recognises both the rewards and the risks present in a market.

Pharma MarketWith regards to assessing risks in the Bangladeshi healthcare sector, we have identified those emanating from the state’s political/economic profile (such as high inflation) and industry specific dangers (such as low per-capita spending and poor access to healthcare facilities) that call into question the likelihood of anticipated returns being realised over the assessed time period.

Risk/Reward Ratings : While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies such as Bangladesh may be a favourable strategy for any multinational pharmaceutical company – it is vital that a company recognises both the rewards and the risks present in a market. For Q, Bangladesh has retained its 17th position out of the 18 regional markets surveyed. Its overall rating of 38.3, remains considerably lower than the average for the region.

Competitive Landscape:

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Companies Mentioned:

  • Beximco Pharmaceuticals
  • Eskayef
  • Novartis
  • Renata
  • Sanofi
  • Square P

Share: